The anabolic effects of parathyroid hormone (PTH) on bone formation are impaired by concurrent use of antiresorptive drugs. We found that the release of active transforming growth factor (TGF)-β1 during osteoclastic bone resorption is inhibited by alendronate. We showed that mouse Sca-1-positive (Sca-1 +) bone marrow stromal cells are a skeletal stem cell subset, which are recruited to bone remodeling sites by active TGF-β1 in response to bone resorption. Alendronate inhibits the release of active TGF-β1 and the recruitment of Sca-1 + skeletal stem cells for the bone formation. The observation was validated in a Tgfb1 -/- mouse model, in which the anabolic effects of PTH on bone formation are diminished. The PTH-stimulated recruitment of in...
Combining anticatabolic agents with parathyroid hormone (PTH) to enhance bone mass has yielded mixed...
We report that a therapeutic dose of the antiresorptive bisphosphonate alendronate administered to s...
Androgen deficiency or androgen receptor knockout (ARKO) causes high-turnover osteopenia, but the ta...
SummaryThe anabolic effects of parathyroid hormone (PTH) on bone formation are impaired by concurren...
PTH stimulates osteoblastic cells to form new bone and to produce osteoblast-osteoclast coupling fac...
The contribution of remodeling-based bone formation coupled to osteoclast activity versus modeling-b...
IntroductionWhile the anti-resorptive effects of the bisphosphonates (BPs) are well documented, many...
[Abstract] Parathyroid hormone (PTH) is a potent bone-forming agent that increases bone mineral dens...
Introduction:Parathyroid hormone increases bone strength primarily by stimulating bone formation, wh...
In bone, haematopoietic cells occupy a specialized microenvironment called the haematopoietic stem c...
Apoptosis of osteocytes and osteoblasts precedes bone resorption and bone loss with reduced mechanic...
Skeletal remodeling requires recruitment of osteoblast precursors, in the form of MSCs, to the bone ...
Contains fulltext : 70385.pdf (publisher's version ) (Open Access)TRPV5 is a Ca(2+...
Although the nonselective β-blocker, propranolol, improves bone density with parathyroid hormone (PT...
Objectives: Various conditions like osteoporosis and Paget’s disease show altered bone homeostasis s...
Combining anticatabolic agents with parathyroid hormone (PTH) to enhance bone mass has yielded mixed...
We report that a therapeutic dose of the antiresorptive bisphosphonate alendronate administered to s...
Androgen deficiency or androgen receptor knockout (ARKO) causes high-turnover osteopenia, but the ta...
SummaryThe anabolic effects of parathyroid hormone (PTH) on bone formation are impaired by concurren...
PTH stimulates osteoblastic cells to form new bone and to produce osteoblast-osteoclast coupling fac...
The contribution of remodeling-based bone formation coupled to osteoclast activity versus modeling-b...
IntroductionWhile the anti-resorptive effects of the bisphosphonates (BPs) are well documented, many...
[Abstract] Parathyroid hormone (PTH) is a potent bone-forming agent that increases bone mineral dens...
Introduction:Parathyroid hormone increases bone strength primarily by stimulating bone formation, wh...
In bone, haematopoietic cells occupy a specialized microenvironment called the haematopoietic stem c...
Apoptosis of osteocytes and osteoblasts precedes bone resorption and bone loss with reduced mechanic...
Skeletal remodeling requires recruitment of osteoblast precursors, in the form of MSCs, to the bone ...
Contains fulltext : 70385.pdf (publisher's version ) (Open Access)TRPV5 is a Ca(2+...
Although the nonselective β-blocker, propranolol, improves bone density with parathyroid hormone (PT...
Objectives: Various conditions like osteoporosis and Paget’s disease show altered bone homeostasis s...
Combining anticatabolic agents with parathyroid hormone (PTH) to enhance bone mass has yielded mixed...
We report that a therapeutic dose of the antiresorptive bisphosphonate alendronate administered to s...
Androgen deficiency or androgen receptor knockout (ARKO) causes high-turnover osteopenia, but the ta...